secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001193125-24-086031
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda's Fanapt receives FDA approval for bipolar I disorder indication
----------------------------------------------------------------------

- FDA approved Fanapt (iloperidone) on April 2, 2024 for acute treatment of manic or mixed episodes in bipolar I disorder in adults.
- Approval based on pivotal study of ~400 patients; primary endpoint YMRS at Week 4 highly statistically significant (p=0.000008).
- Fanapt was previously approved for schizophrenia in 2009; safety profile consistent across indications.
- Vanda CEO cites significant increase in commercial opportunity; bipolar I disorder affects ~10M Americans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524086031/0001193125-24-086031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524086031/d819383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-086031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer